Paolo Gandellini

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 18

Top Venues

Fondazione IRCCS Istituto Nazionale dei Tumori

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Fondazione IRCCS Istituto Nazionale dei Tumori

Italy

Team Leader :: Dept. Experimental Oncology and Molecular Medicine

University of Milan Dec 28 2018

Italy

Assistant Professor :: Biosciences

Publications

Giulia Pagani, Paolo Gandellini
Cleavage and polyadenylation machinery as a novel targetable vulnerability for human cancer. Cancer gene therapy (2024)
Cecilia Pandini, Giulia Pagani, Martina Tassinari, Emanuele Vitale, Eugenia Bezzecchi, Mona Kamal Saadeldin, Valentina Doldi, Giuliana Giannuzzi, Roberto Mantovani, Matteo Chiara, Alessia Ciarrocchi, Paolo Gandellini
The pancancer overexpressed NFYC Antisense 1 controls cell cycle mitotic progression through in cis and in trans modes of action. Cell death & disease 15 (3) (2024)
Cecilia Pandini, Giulia Pagani, Martina Tassinari, Emanuele Vitale, Eugenia Bezzecchi, Mona Kamal Saadeldin, Valentina Doldi, Giuliana Giannuzzi, Roberto Mantovani, Matteo Chiara, Alessia Ciarrocchi, Paolo Gandellini
The pancancer overexpressed NFYC Antisense 1 controls cell cycle mitotic progression through in cis and in trans modes of action. Cell death & disease 15 (3) (2024)
Cecilia Pandini, Giulia Pagani, Martina Tassinari, Emanuele Vitale, Eugenia Bezzecchi, Mona Kamal Saadeldin, Valentina Doldi, Giuliana Giannuzzi, Roberto Mantovani, Matteo Chiara, Alessia Ciarrocchi, Paolo Gandellini
The pancancer overexpressed NFYC Antisense 1 controls cell cycle mitotic progression through in cis and in trans modes of action. Cell death & disease 15 (3) (2024)
Giulia Pagani, Paolo Gandellini
Cleavage and polyadenylation machinery as a novel targetable vulnerability for human cancer. Cancer gene therapy 31 (7) (2024)
Cecilia Pandini, Federica Rey, Cristina Cereda, Stephana Carelli, Paolo Gandellini
Study of lncRNAs in Pediatric Neurological Diseases: Methods, Analysis of the State-of-Art and Possible Therapeutic Implications. Pharmaceuticals (Basel, Switzerland) 16 (11) (2023)
Giulia Pagani, Cecilia Pandini, Paolo Gandellini
Navigating the Multiverse of Antisense RNAs: The Transcription- and RNA-Dependent Dimension. Non-coding RNA 8 (6) (2022)
Valentina Doldi, Mara Lecchi, Silva Ljevar, Maurizio Colecchia, Elisa Campi, Giovanni Centonze, Cristina Marenghi, Tiziana Rancati, Rosalba Miceli, Paolo Verderio, Riccardo Valdagni, Paolo Gandellini, Nadia Zaffaroni
Potential of the Stromal Matricellular Protein Periostin as a Biomarker to Improve Risk Assessment in Prostate Cancer. International journal of molecular sciences 23 (14) (2022)
Rihan El Bezawy, Stefano Percio, Chiara Maura Ciniselli, Michelandrea De Cesare, Gennaro Colella, Matteo Dugo, Silvia Veneroni, Valentina Doldi, Silvia Martini, Dario Baratti, Shigeki Kusamura, Paolo Verderio, Marcello Deraco, Paolo Gandellini, Nadia Zaffaroni, Valentina Zuco
miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma. Cancer gene therapy 29 (10) (2022)
Andrew Chin, Javier Mariscal, Minhyung Kim, Giorgia Guerra, Blandine Victor, Chen Qian, Elisabetta Broseghini, Edwin Posadas, Michael R Freeman, Shivani Sharma, Paolo Gandellini, Nadia Zaffaroni, Sungyong You, Keith Syson Chan, Jlenia Guarnerio, Muller Fabbri, Dolores Di Vizio
miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. Cancers 13 (22) (2021)
Paolo Gandellini, Chiara Maura Ciniselli, Tiziana Rancati, Cristina Marenghi, Valentina Doldi, Rihan El Bezawy, Mara Lecchi, Melanie Claps, Mario Catanzaro, Barbara Avuzzi, Elisa Campi, Maurizio Colecchia, Fabio Badenchini, Paolo Verderio, Riccardo Valdagni, Nadia Zaffaroni
Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables. Cancers 13 (10) (2021)
Martina Tassinari, Paolo Gandellini
Noncoding RNAs in the Interplay between Tumor Cells and Cancer-Associated Fibroblasts: Signals to Catch and Targets to Hit. Cancers 13 (4) (2021)
Rihan El Bezawy, Martina Tripari, Stefano Percio, Alessandro Cicchetti, Monica Tortoreto, Claudio Stucchi, Stella Tinelli, Valentina Zuco, Valentina Doldi, Paolo Gandellini, Riccardo Valdagni, Nadia Zaffaroni
SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair. Cancers 12 (6) (2020)
Federica Rotundo, Denis Cominetti, Rihan El Bezawy, Stefano Percio, Valentina Doldi, Monica Tortoreto, Valentina Zuco, Riccardo Valdagni, Nadia Zaffaroni, Paolo Gandellini
miR-1272 Exerts Tumor-Suppressive Functions in Prostate Cancer via HIP1 Suppression. Cells 9 (2) (2020)
Erica Gentilin, Paolo Gandellini
Coding the noncoding: 2 years of advances in the field of microRNAs and long noncoding RNAs. Cancer gene therapy 28 (5) (2020)
Elena Ferrari, Paolo Gandellini
Unveiling the ups and downs of miR-205 in physiology and cancer: transcriptional and post-transcriptional mechanisms. Cell death & disease 11 (11) (2020)
Valentina Profumo, Barbara Forte, Stefano Percio, Federica Rotundo, Valentina Doldi, Elena Ferrari, Nicola Fenderico, Matteo Dugo, Dario Romagnoli, Matteo Benelli, Riccardo Valdagni, Diletta Dolfini, Nadia Zaffaroni, Paolo Gandellini
LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation. Nature communications 10 (1) (2019)
Maurizio Callari, Paolo Gandellini, Ira Skvortsova, Paul N Span
Predicting and Understanding Cancer Response to Treatment. Disease markers 2018 (2018)
Paolo Gandellini, Elisa Giovannetti, Francesco Nicassio
MicroRNAs in Cancer Management: Big Challenges for Small Molecules. BioMed research international 2015 (2015)

Paolo Gandellini.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Paolo Gandellini